HER2 as a Therapeutic Target in Ovarian Cancer

Members of the human epidermal growth factor receptor (HER) family—epidermal growth factor receptor (EGFR, HER1), HER2, HER3, and HER4—are transmembrane tyrosine kinase receptors that are important mediators of cell growth, development, and survival. Activation of the HER tyrosine kinases triggers intracellular signaling pathways, including the MAPK and PI3K-Akt pathways (Olayioye et al., 2000) (Figure 1).

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  2012-02-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.5772/29064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene.

  2021cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies

  2011influential reference
• Personalized colon cancer care in 2010.

  2011cited by this paper
• Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

  2011cited by this paper
• Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

  2011cited by this paper
• Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

  2011influential reference
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.

  2011cited by this paper
• Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers

  2011cited by this paper
• The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer

  2011cited by this paper
• Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

  2011influential reference
• Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.

  2011cited by this paper
• A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.

  2011cited by this paper
• Quantitative Determination of Estrogen Receptor, Progesterone Receptor, and HER2 mRNA in Formalin-fixed Paraffin-embedded Tissue—A New Option for Predictive Biomarker Assessment in Breast Cancer

  2011cited by this paper
• Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2‐driven cancer cell growth

  2011cited by this paper
• An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010influential reference
• CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.

  2010cited by this paper
• Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft

  2010influential reference
• Abstract 3485: MM-111, an ErbB2/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells driven by the ErbB2/ErbB3 oncogenic unit

  2010cited by this paper
• Diverse somatic mutation patterns and pathway alterations in human cancers.

  2010cited by this paper
• EGF receptor in lung cancer: a successful story of targeted therapy

  2010cited by this paper
• Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

  2010influential reference
• Pertuzumab for the treatment of ovarian cancer

  2010cited by this paper
• HER3 mRNA as a predictive biomarker in anticancer therapy

  2010influential reference
• Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab

  2009cited by this paper
• Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity

  2009influential reference
• Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges

  2009cited by this paper
• Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

  2009influential reference
• A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.

  2009cited by this paper
• Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

  2009cited by this paper
• The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.

  2009cited by this paper
• Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.

  2009cited by this paper
• From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs

  2009cited by this paper
• Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines

  2009cited by this paper
• Molecular predictive and prognostic markers in non-small-cell lung cancer.

  2009cited by this paper
• Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors

  2008influential reference
• Herceptin–Platinum(II) Binding Complexes: Novel Cancer‐Cell‐Specific Agents

  2008cited by this paper
• Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients

  2008cited by this paper
• A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

  2008cited by this paper
• A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.

  2008cited by this paper
• Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.

  2008cited by this paper
• A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer

  2008cited by this paper
• [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.

  2007cited by this paper
• HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients

  2007cited by this paper
• Targeting HER proteins in cancer therapy and the role of the non-target HER3

  2007cited by this paper
• In vivo Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas

  2007influential reference
• Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

  2007cited by this paper
• Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.

  2007cited by this paper
• Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.

  2007cited by this paper
• The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer

  2006cited by this paper
• Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006influential reference
• Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms

  2006cited by this paper
• Mutation analysis of 24 known cancer genes in the NCI-60 cell line set

  2006cited by this paper
• Role of the epidermal growth factor network in ovarian follicles.

  2006cited by this paper
• Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

  2006cited by this paper
• Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.

  2006cited by this paper
• ErbB-3 predicts survival in ovarian cancer.

  2006influential reference
• Simultaneous Quantitative Detection of Relevant Biomarkers in Breast Cancer by Quantitative Real-Time PCR

  2006cited by this paper
• HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.

  2006influential reference
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006influential reference
• Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

  2006influential reference
• An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

  2006cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005influential reference
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Expression ofHer2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma

  2005cited by this paper
• Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer

  2005cited by this paper
• Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma

  2005cited by this paper
• HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance

  2005cited by this paper
• Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.

  2004cited by this paper
• The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.

  2004cited by this paper
• ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.

  2004cited by this paper
• In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.

  2004cited by this paper
• Athletics: Momentous sprint at the 2156 Olympics?

  2004cited by this paper
• TP53 status determines clinical significance of ERBB2 expression in ovarian cancer

  2004cited by this paper
• Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.

  2003cited by this paper
• Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma

  2003cited by this paper
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

  2003cited by this paper
• Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer

  2003cited by this paper
• The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.

  2003cited by this paper
• Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Characteristics of EGFR family‐mediated HRG signals in human ovarian cancer

  1999cited by this paper
• Overexpression of the Oncogene c‐erbB-2 (HER2/neu) and Response to Chemotherapy in Patients with Ovarian Cancer

  1998cited by this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cited by this paper
• Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions

  1996cited by this paper
• A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

  1996cited by this paper
• Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.

  1996cited by this paper
• EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value.

  1995cited by this paper
• Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression.

  1994cited by this paper
• Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy.

  1993cited by this paper
• Prognostic significance of HER‐2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis

  1993cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Molecular Cell Biology

  1986cited by this paper
• Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

  1985cited by this paper
• The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

  1984cited by this paper
• Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

  1984cited by this paper

• Monitoring the Crosstalk Between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 with PET

  2020cites this paper
• Cancer of Reproductive System: Receptors and Targeting Strategies

  2019cites this paper
• Targeted Intracellular Drug Delivery by Receptor Mediated Endocytosis

  2019influential citation
• In-vitro evaluation of HSP27 inhibitors function through HER2 pathway for ovarian cancer therapy

  2018cites this paper
• Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas

  2017cites this paper
• Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling.

  2015cites this paper
• Anti-angiogenic Therapy Versus Dose-Dense Paclitaxel Therapy for Frontline Treatment of Epithelial Ovarian Cancer: Review of Phase III Randomized Clinical Trials

  2014cites this paper
• An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers

  2014cites this paper
• Immunohistochemical expression of Her-2/neu in surface epithelial carcinoma of the ovary

  year unknowncites this paper